M&T Bank Corp grew its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 18.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,437 shares of the biotechnology company’s stock after buying an additional 535 shares during the period. M&T Bank Corp’s holdings in Axon Enterprise were worth $887,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of AXON. Sands Capital Management LLC boosted its stake in shares of Axon Enterprise by 31.1% during the third quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company’s stock valued at $519,823,000 after purchasing an additional 619,179 shares during the period. Wellington Management Group LLP grew its stake in Axon Enterprise by 3.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company’s stock worth $389,229,000 after acquiring an additional 62,324 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of Axon Enterprise by 184.3% during the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock worth $138,535,000 after acquiring an additional 451,350 shares during the period. Northern Trust Corp raised its stake in shares of Axon Enterprise by 3.1% during the third quarter. Northern Trust Corp now owns 631,212 shares of the biotechnology company’s stock valued at $125,605,000 after acquiring an additional 19,068 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Axon Enterprise by 1.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 564,917 shares of the biotechnology company’s stock valued at $112,413,000 after purchasing an additional 8,127 shares during the period. 79.08% of the stock is owned by institutional investors.
Axon Enterprise Stock Down 1.8 %
Shares of AXON stock opened at $303.43 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. Axon Enterprise, Inc. has a fifty-two week low of $175.37 and a fifty-two week high of $329.87. The firm has a market capitalization of $22.90 billion, a PE ratio of 88.72 and a beta of 0.91. The stock’s 50-day simple moving average is $310.64 and its 200-day simple moving average is $269.19.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business had revenue of $460.74 million during the quarter, compared to analysts’ expectations of $441.57 million. During the same period in the previous year, the business posted $0.51 EPS. The business’s quarterly revenue was up 34.3% compared to the same quarter last year. Equities analysts expect that Axon Enterprise, Inc. will post 2.44 earnings per share for the current year.
Wall Street Analysts Forecast Growth
AXON has been the topic of several research reports. Robert W. Baird raised their price objective on Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 22nd. The Goldman Sachs Group upped their price objective on shares of Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. TheStreet cut shares of Axon Enterprise from a “b” rating to a “c+” rating in a research report on Tuesday, February 27th. JMP Securities reissued a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 target price on shares of Axon Enterprise in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus price target of $335.27.
Get Our Latest Stock Analysis on AXON
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.
